Mitsuomi Hirashima, who is a former professor in the Department of Immunology and Immunopathology at Kagawa Medical University (now Faculty of Medicine, Kagawa University) and now a representative director of GalPharma, identified galectin-9 as a novel eosinophil chemoattractant in 1998 and continued his research energetically on the physiologically active endogenous substance galectin. GalPharma is a university-launched venture company that was established in November 2000 in order to translate his research results into practical application. Our technologies are based on the research results obtained by Professor Hirashima and his team at the Faculty of Medicine, Kagawa University. Run in collaboration with industry, government, and academia, GalPharma is a company to make efforts to be a role model as the contribution of a local university to the local community by returning advanced science and technology to society, activating regional industry, and developing the regional society and economy.